NYSE EURONEXT - EURONEXT BRUSSELS · UCBJY
+0.00% · +$0.0000 · Vol Not reported
Market closed · last close shown
Ucb SA

Ucb SA

Pharmaceuticals
$129.23
Card
Relationship Map

Veridion Score

Refresh
Score snapshot refresh in progress
Veridion Score History · 90D
Score not reportedVeridion does not publish a score-history trend for UCBJY until the ticker has a real scored snapshot. No trend is implied for this page.Review methodology
AI Analysis
Sovereign

Why is UCBJY moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading UCBJY catalysts
About Ucb SA
Pharmaceuticals
Listed since
1987
Country
BE

UCB SA UNSP/ADR

Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$129.23
Last session
Day high
$129.23
Last session
Day low
$129.23
Last session
Previous close
$129.23
52W high
$168.19
-23.16% from high
52W low
$115.23
26% of range
Market cap
$42.1B
P/E
27.05×
EPS
$8.02
Beta
0.05
Avg volume
43.6K
VWAP
$129.23
Last session
Price history computed in-house
1W
+3.87%
1M
-7.04%
3M
-9.07%
1Y
+11.46%
YTD
-7.53%
SMA 50 $137.87 · below
SMA 200 $143.45 · below
52W position 26%

UCBJY overview

Loading financial statements
Loading UCBJY Form 4 filings
Public disclosures

Congress activity in UCBJY

No receipt-qualified Congressional disclosure is present for UCBJY in the cached public ledger.

Federal contracts

UCBJY contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for UCBJY in this window.
Lobbying spend

UCBJY lobbying filings, year to date.

Registered lobbying filings matched to Ucb SA.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for UCBJY in this window.
Loading news for UCBJY
Analyst ratings
Sovereign unlock shows live analyst consensus for UCBJY.
Options
Sovereign unlock shows live options positioning for UCBJY.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.